Agilent agrees to buy digital pathology software provider Proscia for $240 million cash upfront

• Agilent agreed to buy digital pathology software provider Proscia in an all-cash deal valued at USD 240 million at closing.
• Deal includes up to USD 30 million in additional payments tied to future performance milestones.
• Proscia serves more than 4,000 labs, hospitals, and clinics, with trailing 12-month revenue exceeding USD 18 million.
• Transaction expected to close early in Agilent’s fiscal year 2027; Proscia will join its Life Sciences and Diagnostics Markets Group.
• Acquisition expands Agilent’s digital pathology footprint, adding vendor-agnostic workflow software with FDA 510(k) clearance for primary diagnosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013873030) on October 13, 2026, and is solely responsible for the information contained therein.